Litcius/Paper detail

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, Silvio Danese, Maria Kłopocka, Jarosław Kierkuś, Roman Kulynych, Maciej Gonciarz, Artur Sołtysiak, Patryk Smoliński, Slobodan Srećković, Ekaterina Valuyskikh, Adi Lahat, M. Horyński, Antonio Gasbarrini, М. Ф. Осипенко, Vladimir Borzan, Maciej Kowalski, Daria V. Saenko, Ruslan Sardinov, Sang Joon Lee, SungHyun Kim, Yunju Bae, Sunhee Lee, Seulgi Lee, Joon Ho Lee, Siyoung Yang, Jimin Lee, Juhyun Lee, Jong‐Min Kim, Gahee Park, William J. Sandborn, Jean–Frédéric Colombel

2024Gastroenterology60 citationsDOI

Topics & Concepts

InfliximabMedicineInflammatory bowel diseaseMaintenance therapyRandomized controlled trialDiseaseInternal medicineGastroenterologySurgeryChemotherapyBiosimilars and Bioanalytical MethodsInflammatory Bowel DiseaseMicroscopic Colitis
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) | Litcius